Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Time to Strategy Failure and Treatment Beyond Progression in Pretreated Metastatic Renal Cell Carcinoma Patients Receiving Nivolumab: Post-Hoc Analysis of the Meet-URO 15 Study

Veronica Murianni,Alessio Signori,Sebastiano Buti,Sara Elena Rebuzzi,Davide Bimbatti,Ugo De Giorgi,Silvia Chiellino,Luca Galli,Paolo Andrea Zucali,Cristina Masini,Emanuele Naglieri,Giuseppe Procopio,Michele Milella,Lucia Fratino,Cinzia Baldessari,Riccardo Ricotta,Veronica Mollica,Mariella Soraru,Marianna Tudini,Veronica Prati,Andrea Malgeri,Francesco Atzori,Marilena Di Napoli,Orazio Caffo,Massimiliano Spada,Franco Morelli,Giuseppe Prati,Franco Nole,Francesca Vignani,Alessia Cavo,Helga Lipari,Giandomenico Roviello,Fabio Catalano,Alessandra Damassi,Malvina Cremante,Pasquale Rescigno,Giuseppe Fornarini,Giuseppe Luigi Banna

Frontiers in Oncology（2024）

Cited 0|Views52
Key words
metastatic renal cell carcinoma,immunotherapy,immune checkpoint inhibitors,nivolumab,treatment beyond progression,time to strategy failure,time to treatment failure
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined